RPRX — Royalty Pharma plc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1802768 ·
Last close
$59.22
Market Cap
$26.37B
52W High
$60.44
52W Low
$51.15
ADV30
2,906,915
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 674,141,000 | — | 133,119,000 | 17,883,000 | 19,819,771,000 | 811,986,000 | 10,034,057,000 |
| Mar 2026 | 630,576,000 | — | 632,481,000 | 294,690,000 | 19,815,415,000 | 586,395,000 | 9,878,582,000 |
| Dec 2025 | 621,990,000 | — | 388,382,000 | 214,205,000 | 19,620,780,000 | 618,696,000 | 9,905,841,000 |
| Sep 2025 | 609,291,000 | — | 427,156,000 | 288,217,000 | 19,347,280,000 | 938,944,000 | 9,726,419,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$2,976,457,000
Investing CF
$-2,513,702,000
Financing CF
$-282,677,000
CapEx
—
Dividends Paid
$-399,061,000
Buybacks
$-321,773,000
EPS Diluted TTM
$1.61
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$2,459,089,000
Inventory
—
Receivables
$31,474,000
ST Investments
$914,454,000
EBIT TTM
$1,710,940,000
Pretax Income TTM
$1,349,866,000
Interest Exp TTM
$361,074,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$2,535,997,952
EBITDA
$1,557,374,976
Free Cash Flow
$-1,195,372,160
Enterprise Value
$37,447,204,864
Total Cash
$836,985,984
Total Debt
$8,961,892,352
Shares Out
445,277,344
Trailing EPS
$1.91
Book Value
$15.53
ROE
14.0%
ROA
5.1%
Div Yield
1.63%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,378,193,000 | 1,559,518,000 | 770,947,000 | 19,620,780,000 | 9,905,841,000 | — | 2,489,823,000 |
| Dec 2024 | 2,263,576,000 | 1,292,444,000 | 858,983,000 | 18,222,715,000 | 7,880,349,000 | — | 2,768,986,000 |
| Dec 2023 | 2,354,554,000 | 1,492,150,000 | 1,134,834,000 | 16,381,851,000 | 6,297,562,000 | — | 2,987,802,000 |
| Dec 2022 | 2,237,215,000 | 922,892,000 | 42,832,000 | 16,813,466,000 | 7,288,093,000 | — | 2,143,980,000 |
TTM Snapshot
Revenues TTM
$2,260,239,000
NetIncome TTM
$860,681,000
OpCashFlow TTM
$0
Assets (Latest)
$18,222,715,000
Forward EPS
$5.74
Max Pain — expiry 2026-12-18
max pain strike: $42.50 · spot: $58.56 · call oi: 4,932 · put oi: 933
Expected Move to 2026-12-18:
±$6.82
(11.65%) —
implied range
$51.74 –
$65.39
· ATM straddle on $57.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ROIV | Roivant Sciences Ltd. | $26.12B | $36.16 | — |
| INSM | INSMED Inc | $28.89B | $132.28 | — |
| BEIGF | BeOne Medicines Ltd. | $29.75B | $21.95 | — |
| ALNY | ALNYLAM PHARMACEUTICALS, INC. | $29.97B | $223.95 | — |
| ZTS | Zoetis Inc. | $30.39B | $73.54 | — |
News headlines (Yahoo Finance, 1h cache)
Zealand Pharma (CPSE:ZEAL) On Its Royalty Pharma Deal And The Fair Value Debate
2026-08-12 23:16 · Yahoo
Royalty Pharma (RPRX) Q2 2026 Earnings Call Transcript
2026-08-12 13:59 · Yahoo
Royalty Pharma Q2 Earnings Call Highlights
2026-08-05 19:04 · Yahoo
Royalty Pharma PLC (RPRX) (Q2 2026) Earnings Call Highlights: Strong Growth and Raised Guidance
2026-08-05 19:01 · Yahoo
Royalty Pharma (RPRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
2026-08-05 13:30 · Yahoo
Gear Up for Royalty Pharma (RPRX) Q2 Earnings: Wall Street Estimates for Key Metrics
2026-08-04 13:15 · Yahoo
Royalty Pharma appoints Greg Raskin as Senior Vice President, Head of Academic Initiatives
2026-08-03 12:15 · Yahoo
Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune
2026-07-22 11:05 · Yahoo
Neurimmune sells a portion of its royalty interest in cliramitug to Royalty Pharma
2026-07-22 10:50 · Yahoo
Royalty Pharma (RPRX) Crossed Above the 20-Day Moving Average: What That Means for Investors
2026-08-13 13:35 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.